{"entity":{"id":"nct06973187","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","aka":[],"tldr":"A phase 3 trial of Pirtobrutinib in chronic lymphocytic leukaemia, run by BeOne Medicines, now recruiting.","summary":"A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma is a phase 3 interventional study registered as NCT06973187 by BeOne Medicines, with 500 participants planned, started 2025-09-04 and due to reach its primary completion in 2028-04-17. Interventions recorded: Tacabrutideg and Pirtobrutinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06973187","url":"https://clinicaltrials.gov/study/NCT06973187"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cll","cll-relapsed"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["pirtobrutinib"],"companies":["beone"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06973187","phase":"3","setting":"A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","sponsor":"BeOne Medicines","participation":[{"nct":"NCT06973187","source":"https://clinicaltrials.gov/study/NCT06973187","fetchedAt":"2026-10-07T16:55:20.203Z","studySha256":"3f05a7495e47613bb6ae956591f688b03b9f164294cd2b74d1854229d3c5d36f","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-28","leadSponsor":"BeOne Medicines","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":500,"enrolmentType":"ESTIMATED","siteCount":217,"recruitingSiteCount":217,"countries":["Argentina","Australia","Austria","Belgium","Brazil","China","France","Germany","Israel","Italy","Japan","Mexico","Netherlands","New Zealand","Poland","Puerto Rico","Romania","Singapore","South Korea","Spain","Sweden","Switzerland","United Kingdom","United States"]}],"started":"2025-09-04","startedType":"actual","enrolled":500,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06973187/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"cll-relapsed","kind":"cancer","name":"Relapsed or refractory chronic lymphocytic leukaemia","route":"/cancers/cll-relapsed/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"pirtobrutinib","kind":"drug","name":"Pirtobrutinib","route":"/drugs/pirtobrutinib/"}],"company":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}]}}